BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16704441)

  • 1. Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome.
    Al-Ahmari A; Shah N; Sung L; Zipursky A; Hitzler J
    Br J Haematol; 2006 Jun; 133(6):646-8. PubMed ID: 16704441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group.
    Kudo K; Kojima S; Tabuchi K; Yabe H; Tawa A; Imaizumi M; Hanada R; Hamamoto K; Kobayashi R; Morimoto A; Nakayama H; Tsuchida M; Horibe K; Kigasawa H; Tsukimoto I;
    J Clin Oncol; 2007 Dec; 25(34):5442-7. PubMed ID: 18048827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis.
    Ariffin H; Garcia JC; Daud SS; Ibrahim K; Aizah N; Ong GB; Chong LA; Mohamad Z
    Pediatr Blood Cancer; 2009 Jul; 53(1):108-11. PubMed ID: 19260099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute megakaryoblastic leukaemia (AMKL) in children: a comparison of AMKL with and without Down syndrome.
    Hama A; Yagasaki H; Takahashi Y; Nishio N; Muramatsu H; Yoshida N; Tanaka M; Hidaka H; Watanabe N; Yoshimi A; Matsumoto K; Kudo K; Kato K; Horibe K; Kojima S
    Br J Haematol; 2008 Mar; 140(5):552-61. PubMed ID: 18275433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
    Creutzig U; Reinhardt D; Diekamp S; Dworzak M; Stary J; Zimmermann M
    Leukemia; 2005 Aug; 19(8):1355-60. PubMed ID: 15920490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
    Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
    Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature.
    Abildgaard L; Ellebaek E; Gustafsson G; Abrahamsson J; Hovi L; Jonmundsson G; Zeller B; Hasle H
    Ann Hematol; 2006 May; 85(5):275-80. PubMed ID: 16518605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid leukaemia in children with Down syndrome: report of the registry-based French experience between 1990 and 2003.
    Tandonnet J; Clavel J; Baruchel A; Nacka F; Pérel Y
    Pediatr Blood Cancer; 2010 Jul; 54(7):927-33. PubMed ID: 20405513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study.
    Taga T; Shimomura Y; Horikoshi Y; Ogawa A; Itoh M; Okada M; Ueyama J; Higa T; Watanabe A; Kanegane H; Iwai A; Saiwakawa Y; Kogawa K; Yamanaka J; Tsurusawa M
    Pediatr Blood Cancer; 2011 Jul; 57(1):36-40. PubMed ID: 21557456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down syndrome, drug metabolism and chromosome 21.
    Taub JW; Ge Y
    Pediatr Blood Cancer; 2005 Jan; 44(1):33-9. PubMed ID: 15390307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with Down syndrome.
    Shah N; Al-Ahmari A; Al-Yamani A; Dupuis L; Stephens D; Hitzler J
    Pediatr Blood Cancer; 2009 Jan; 52(1):14-9. PubMed ID: 18802938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy.
    Kudo K; Hama A; Kojima S; Ishii R; Morimoto A; Bessho F; Sunami S; Kobayashi N; Kinoshita A; Okimoto Y; Tawa A; Tsukimoto I
    Int J Hematol; 2010 May; 91(4):630-5. PubMed ID: 20237876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
    Langebrake C; Creutzig U; Reinhardt D
    Klin Padiatr; 2005; 217(3):126-34. PubMed ID: 15858703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythroblastic and/or megakaryoblastic leukemia in Down syndrome: treatment with low-dose arabinosyl cytosine.
    Tchernia G; Lejeune F; Boccara JF; Denavit MF; Dommergues JP; Bernaudin F
    J Pediatr Hematol Oncol; 1996 Feb; 18(1):59-62. PubMed ID: 8556372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis.
    Roy A; Roberts I; Norton A; Vyas P
    Br J Haematol; 2009 Oct; 147(1):3-12. PubMed ID: 19594743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute megakaryoblastic leukemia in Down syndrome.
    Hitzler JK
    Pediatr Blood Cancer; 2007 Dec; 49(7 Suppl):1066-9. PubMed ID: 17943965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review.
    Gamis AS
    Pediatr Blood Cancer; 2005 Jan; 44(1):13-20. PubMed ID: 15534881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
    Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing therapy for myeloid disorders of Down syndrome.
    Webb DK
    Br J Haematol; 2005 Oct; 131(1):3-7. PubMed ID: 16173956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.